Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omicron variant booster vaccines versus prototype mRNA-1273 as fourth-dose booster
2022-000063-51Phase 2
- Sponsor
- Moderna Inc
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing mRNA-1273.529 booster, mRNA-1273.214 booster and mRNA-1273 prototype booster (3 arms). Primary endpoint: Geometric Mean Titer of mRNA-1273.529 and mRNA-1273 against the B.1.1.529 strain.
02
Drugs
mRNA-1273.529elasomeran + imelasomeranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000063-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000063-51.